68 related articles for article (PubMed ID: 15655052)
1. Reasons for non-treatment of hepatitis C in veterans in care.
Butt AA; Wagener M; Shakil AO; Ahmad J
J Viral Hepat; 2005 Jan; 12(1):81-5. PubMed ID: 15655052
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life.
Cacoub P; Rosenthal E; Halfon P; Sene D; Perronne C; Pol S
J Viral Hepat; 2006 Oct; 13(10):678-82. PubMed ID: 16970599
[TBL] [Abstract][Full Text] [Related]
3. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
Chainuvati S; Khalid SK; Kancir S; Shea M; Edwards J; Sernyak M; Wongcharatrawee S; Garcia-Tsao G
J Viral Hepat; 2006 Apr; 13(4):235-41. PubMed ID: 16611189
[TBL] [Abstract][Full Text] [Related]
4. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care.
Fireman M; Indest DW; Blackwell A; Whitehead AJ; Hauser P
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S286-91. PubMed ID: 15768336
[TBL] [Abstract][Full Text] [Related]
5. Sustained virologic response to treatment in 100% of patients recently infected, nosocomially, with HCV genotype 2.
Sikuler E; Tur-Kaspa R; Shemer-Avni Y; Delgado J; Zilberman D; Fich A; Baruch Y; Hyam E
J Clin Gastroenterol; 2008 Jul; 42(6):730-3. PubMed ID: 18574394
[TBL] [Abstract][Full Text] [Related]
6. Viral RNA testing in hepatitis C antibody-positive veterans.
Rongey CA; Kanwal F; Hoang T; Gifford AL; Asch SM
Am J Prev Med; 2009 Mar; 36(3):235-8. PubMed ID: 19162434
[TBL] [Abstract][Full Text] [Related]
7. Comparison of characteristics of treated and non-treated patients with Hepatitis C infection.
Hare CB; Morris JA; Chu A; Gotz V; Loveland JJ; Hodes D; Klaskala W
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):71-6. PubMed ID: 16136612
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
Hallinan R; Byrne A; Amin J; Dore GJ
J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
[TBL] [Abstract][Full Text] [Related]
9. Compliance with referral for hepatitis C evaluation among veterans.
Brady CW; Coffman CJ; Provenzale D
J Clin Gastroenterol; 2007; 41(10):927-31. PubMed ID: 18090163
[TBL] [Abstract][Full Text] [Related]
10. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre.
Restrepo A; Johnson TC; Widjaja D; Yarmus L; Meyer K; Clain DJ; Bodenheimer HC; Min AD
J Viral Hepat; 2005 Jan; 12(1):86-90. PubMed ID: 15655053
[TBL] [Abstract][Full Text] [Related]
11. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
Dollarhide AW; Loh C; Leckband SG; Endow-Eyer R; Robinson S; Meyer JM
J Clin Gastroenterol; 2007 Mar; 41(3):322-8. PubMed ID: 17426475
[TBL] [Abstract][Full Text] [Related]
12. Outcome of screening for hepatitis C virus infection based on risk factors.
Mallette C; Flynn MA; Promrat K
Am J Gastroenterol; 2008 Jan; 103(1):131-7. PubMed ID: 17894850
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications.
Pradat P; Tillmann HL; Sauleda S; Braconier JH; Saracco G; Thursz M; Goldin R; Winkler R; Alberti A; Esteban JI; Hadziyannis S; Rizzetto M; Thomas H; Manns MP; Trepo C;
J Viral Hepat; 2007 Aug; 14(8):556-63. PubMed ID: 17650289
[TBL] [Abstract][Full Text] [Related]
14. Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study.
Tavakoli-Tabasi S; Rowan P; Abdul-Latif M; Kunik ME; El-Serag HB
Aliment Pharmacol Ther; 2005 Feb; 21(3):235-42. PubMed ID: 15691297
[TBL] [Abstract][Full Text] [Related]
15. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection.
Bini EJ; Bräu N; Currie S; Shen H; Anand BS; Hu KQ; Jeffers L; Ho SB; Johnson D; Schmidt WN; King P; Cheung R; Morgan TR; Awad J; Pedrosa M; Chang KM; Aytaman A; Simon F; Hagedorn C; Moseley R; Ahmad J; Mendenhall C; Waters B; Strader D; Sasaki AW; Rossi S; Wright TL
Am J Gastroenterol; 2005 Aug; 100(8):1772-9. PubMed ID: 16086714
[TBL] [Abstract][Full Text] [Related]
16. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
[TBL] [Abstract][Full Text] [Related]
17. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.
Höroldt B; Haydon G; O'Donnell K; Dudley T; Nightingale P; Mutimer D
Liver Int; 2006 Aug; 26(6):650-9. PubMed ID: 16842320
[TBL] [Abstract][Full Text] [Related]
18. Use of specialty care versus standard retail pharmacies for treatment of hepatitis C.
Cohen SM; Kwasny MJ; Ahn J
Ann Pharmacother; 2009 Feb; 43(2):202-9. PubMed ID: 19193591
[TBL] [Abstract][Full Text] [Related]
19. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.
Yilmaz N; Shiffman ML; Stravitz RT; Sterling RK; Luketic VA; Sanyal AJ; Mills AS; Contos MJ; Coterell A; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2007 Jul; 13(7):975-83. PubMed ID: 17600360
[TBL] [Abstract][Full Text] [Related]
20. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.
Huckans MS; Loftis JM; Blackwell AD; Linke A; Hauser P
Subst Abuse Treat Prev Policy; 2007 Jan; 2():4. PubMed ID: 17222348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
